BeStock  

Adaptive Biotechnologies ADPT

US equityMarket cap rank #2124Diagnostics & Research
$27.93 −$0.12 (-0.43%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.89 -0.14%
Open$27.43
Prev close$28.05
Day range$27.15 – $28.23
Volume2.48M
Market cap$4.52B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$83.90M-10.7% YoY
Operating profit-$457,000.00-104.4% YoY
Net profit$2.81M-70.6% YoY
Diluted EPS$0.02-66.7% YoY
Free cash flow$7.68M+201.9% YoY
Operating cash flow$9.61M

Revenue, last 8 quarters

$47.5MDec '24$52.4MMar '25$58.9MJun '25$94.0MSep '25$71.7MDec '25$70.9MMar '26$71.6MJun '26$83.9MSep '26

Net profit, last 8 quarters

$-33.7MDec '24$-29.8MMar '25$-25.6MJun '25$9.5MSep '25$-13.6MDec '25$-20.0MMar '26$-39.9MJun '26$2.8MSep '26

Diluted EPS by quarter

-0.23Dec '24-0.20Mar '25-0.17Jun '250.06Sep '25-0.09Dec '25-0.13Mar '26-0.25Jun '260.02Sep '26

Free cash flow by quarter

$-12.6MDec '24$-29.7MMar '25$-13.1MJun '25$-7.5MSep '25$1.4MDec '25$-10.3MMar '26$-7.6MJun '26$7.7MSep '26

Annual revenue

$98.4MFY20$154.3MFY21$185.3MFY22$170.3MFY23$179.0MFY24$277.0MFY25

Profitability & balance sheet

Gross margin74.2%
Operating margin-16.2%
Net margin-23.7%
Return on equity-37.1%
Return on assets-12.0%
Return on invested capital-16.5%
Current ratio3.97
Liabilities / assets73.1%
Cash & investments$298.95M
Total debt$399.83M
Net cash (debt)-$100.88M

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Minimal Residual Disease (MRD)$72.57M 86.5%
  • Immune Medicine$11.34M 13.5%

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $83.90M $71.55M $70.87M $276.98M $71.68M
Total Operating Revenue $83.90M $71.55M $70.87M $276.98M $71.68M
Cost of Revenue $19.93M $20.17M $18.71M $71.36M $18.22M
Gross Profit $63.97M $51.39M $52.17M $205.62M $53.46M
Operating Expense $64.43M $67.16M $71.37M $262.74M $66.23M
Selling and Admin Expenses $45.36M $47.58M $47.33M $167.27M $44.04M
-Selling & Marketing Expense $26.90M $26.41M $26.35M $94.57M $24.48M
-General & Admin Expense $18.46M $21.17M $20.98M $72.70M $19.56M
Research & Development $18.64M $19.15M $23.62M $93.77M $21.76M
Depreciation & Amortization & Depletion $428,000.00 $423,000.00 $419,000.00 $1.70M $429,000.00
-Depreciation & Amortization $428,000.00 $423,000.00 $419,000.00 $1.70M $429,000.00
Operating Profit -$457,000.00 -$15.77M -$19.21M -$57.12M -$12.77M
Net Non-Operating Interest Income (Expense) $3.26M -$438,000.00 -$809,000.00 -$2.33M -$806,000.00
Non-Operating Interest Income $3.77M $2.26M $2.08M $9.44M $2.15M
Non-Operating Interest Expense $503,000.00 $2.69M $2.89M $11.78M $2.95M
Special Income (Charges) $0.00 -$23.73M – $0.00 $0.00
Pretax Profit $2.81M -$39.94M -$20.02M -$59.46M -$13.58M
Net Profit $2.81M -$39.94M -$20.02M -$59.46M -$13.58M
Profit from Continuing Operations $2.81M -$39.94M -$20.02M -$59.46M -$13.58M
Minority Interests -$70,000.00 -$153,000.00 $18,000.00 $42,000.00 $0.00
Net Income to Parent Company $2.88M -$39.79M -$20.03M -$59.50M -$13.58M
Net Income to Common Stockholders $2.88M -$39.79M -$20.03M -$59.50M -$13.58M
Basic EPS $0.02 -$0.25 -$0.13 -$0.39 -$0.09
Diluted EPS $0.02 -$0.25 -$0.13 -$0.39 -$0.09
Other Income (Expense) – -$23.73M – – –
-Less:Other Special Charges – $23.73M – – –
-Less:Impairment of Capital Assets – – – $0.00 $0.00

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $683.12M $640.68M $505.94M $512.74M $512.74M
Total Current Assets $392.69M $420.56M $291.81M $300.19M $300.19M
Cash and Cash Equivalents & Short-Term Investments $298.95M $344.26M $218.33M $226.98M $226.98M
-Cash and Cash Equivalents $75.62M $169.87M $77.58M $70.50M $70.50M
-Short Term Investments $223.34M $174.38M $140.75M $156.49M $156.49M
Receivables $66.67M $49.51M $48.32M $50.37M $50.37M
-Accounts Receivable $66.67M $49.51M $48.32M $50.37M $50.37M
Inventory $10.06M $10.50M $11.21M $9.82M $9.82M
Other Current Assets $17.01M $16.30M $13.95M $13.02M $13.02M
Total Non-Current Assets $290.43M $220.12M $214.14M $212.55M $212.55M
Net PPE $65.96M $68.57M $71.02M $74.72M $74.72M
-Gross PPE $65.96M $68.57M $71.02M $170.51M $170.51M
Investments and Advances $101.23M $27.48M $18.89M $13.23M $13.23M
-Available for Sale Securities $101.23M $27.48M $18.89M $13.23M $13.23M
Goodwill and Other Intangible Assets $119.43M $119.86M $120.28M $120.70M $120.70M
-Goodwill $118.97M $118.97M $118.97M $118.97M $118.97M
-Other Intangible Assets $456,000.00 $884,000.00 $1.31M $1.73M $1.73M
Other Non-Current Assets $3.82M $4.21M $3.95M $3.90M $3.90M
Total Liabilities $499.23M $490.02M $281.70M $287.74M $287.74M
Total Current Liabilities $98.97M $87.71M $87.01M $89.92M $89.92M
Payables $6.53M $5.24M $9.62M $7.01M $7.01M
-Accounts Payable $6.53M $5.24M $9.62M $6.47M $6.47M
Current Accrued Expenses $8.20M $10.65M $7.47M $7.16M $7.16M
Short-Term Debt and Capital Lease Obligation $9.14M $8.82M $8.51M $8.92M $8.92M
-Current Capital Lease Obligation $9.14M $8.82M $8.51M $8.92M $8.92M
Current Deferred Liabilities $60.00M $53.26M $49.40M $45.19M $45.19M
Total Non-Current Liabilities $400.26M $402.30M $194.69M $197.82M $197.82M
Long Term Debt and Capital Lease Obligation $399.83M $401.68M $69.12M $70.23M $70.23M
-Long Term Debt $335.38M $334.88M – – –
-Long Term Capital Lease Obligation $64.46M $66.80M $69.12M $70.23M $70.23M
Non-Current Deferred Liabilities $408,000.00 $608,000.00 $807,000.00 $1.01M $1.01M
Other Non-Current Liabilities $20,000.00 $20,000.00 $124.77M $126.59M $126.59M
Total Equity $183.89M $150.66M $224.24M $225.00M $225.00M
Stockholders' Equity $176.21M $142.91M $216.34M $218.79M $218.79M
Capital Stock $16,000.00 $16,000.00 $16,000.00 $15,000.00 $15,000.00
-Common Stock $16,000.00 $16,000.00 $16,000.00 $15,000.00 $15,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.60B $1.57B $1.60B $1.58B $1.58B
Retained Earnings -$1.42B -$1.42B -$1.38B -$1.36B -$1.36B
Gains/Losses Not Affecting Retained Earnings -$1.29M -$212,000.00 -$28,000.00 $253,000.00 $253,000.00
Minority Interests $7.68M $7.75M $7.90M $6.21M $6.21M
Other Current Liabilities – – $5.80M $4.64M $4.64M
-Accumulated Depreciation – – – -$95.79M -$95.79M
-Total Tax Payable – – – $541,000.00 $541,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow $9.61M -$6.40M -$9.54M -$45.99M $2.06M
Net cash flow from continuing operations $9.61M -$6.40M -$9.54M -$45.99M $2.06M
Net Income from Continuing Operations $2.81M -$39.94M -$20.02M -$59.46M -$13.58M
Depreciation & Depletion & Amortization $3.61M $3.70M $3.84M $17.83M $4.20M
Other Non-Cash Items $1.54M $18.61M $807,000.00 $3.87M $843,000.00
Change in Working Capital -$8.02M $222,000.00 -$6.30M -$57.77M -$2.45M
-Change in Receivables -$17.16M -$1.20M $2.05M -$8.65M -$5.54M
-Change in Inventory $489,000.00 $561,000.00 -$1.32M -$998,000.00 -$10,000.00
-Change in Prepaid Assets -$1.45M -$1.70M -$824,000.00 -$1.73M $799,000.00
-Change in Payables and Accrued Expense $5.22M $1.01M -$7.51M $665,000.00 $1.17M
-Change In Other Working Capital $4.88M $1.55M $1.31M -$47.06M $1.14M
Net cash flow from investing -$125.06M -$43.48M $9.14M $37.95M -$8.25M
Net Cash Flow from Continuing Investing Activities -$125.06M -$43.48M $9.14M $37.95M -$8.25M
Net PPE Purchase and Sale -$1.93M -$1.18M -$796,000.00 -$2.96M -$636,000.00
Net Investment Purchase and Sale -$123.13M -$42.29M $9.94M $40.91M -$7.62M
Financing Cash Flow $21.17M $142.19M $7.50M $30.40M $21.66M
Net Cash Flow from Continuing Financing Activities $21.17M $142.19M $7.50M $30.40M $21.66M
Net Issuance Payments Of Debt -$680,000.00 – – – –
Net Common Stock Issuance $0.00 – – – –
Proceeds from Stock Option Exercised $21.85M $5.38M $5.03M $17.88M $9.13M
Net Other Financing Charges $0.00 -$173.71M $2.48M $12.52M –
Ending Cash Balance $78.32M $172.60M $80.29M $73.18M $73.18M
Net Change in Cash -$94.28M $92.31M $7.11M $22.37M $15.46M
Beginning Cash Balance $172.60M $80.29M $73.18M $50.82M $57.72M
Free Cash Flow $7.68M -$7.58M -$10.33M -$48.95M $1.42M

Discussion

No comments yet — be the first to weigh in on ADPT.

Sign in to join the discussion.

Scroll to Top